Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 28, 2014; 20(48): 18070-18091
Published online Dec 28, 2014. doi: 10.3748/wjg.v20.i48.18070
Table 4 Studies and their findings on resistin, visfatin and retinol binding protein 4
ResistinResistin levels increased in morbidly obese humans[142]
Resistin levels in T2DM patients 20% higher when compared to non-diabetic patients[144]
No correlation between resistin and components of MS on T2DM patients[145]
Resistin did not correlate with BMI but significantly correlated with IR[146]
G/G -180C>G homozygotes for resistin had significantly higher resistin mRNA levels in abdominal subcutaneous fat[148]
Serum resistin levels not associated with the presence of NASH[149]
Serum resistin levels higher in NAFLD that in controls and positively correlated with liver inflammation and fibrosis severity[118,150]
Resistin serum levels in NAFLD patients were associated with histological severity of the disease but not with IR[151]
Expression of resistin in human peripheral-blood mononuclear cells upregulated by TNF-α and IL-6[152]
VisfatinSecretion of visfatin enhanced by glucose administration[153]
Plasma visfatin elevated in patients with T2DM[154]
Visfatin plasma concentrations markedly elevated in obese subjectsBariatric surgery reduced body mass index, visfatin, leptin and increased adiponectin after 6 mo[155]
Plasma visfatin levels elevated in subjects with MS[156]
Significantly higher visfatin mRNA in visceral fat of obese subjects compared with lean controls, and positively correlated with body mass index[158]
Visfatin level lower in NASH compared to NAFLD patients and healthy controls[159]
Visfatin level positively correlated with portal inflammation[160]
Retinol binding protein 4Serum RBP4 concentration elevated in IR, obese humans, T2DM and in subjects with a strong family history of T2DM[161,162]
Strong association of increased circulating RBP4 levels with IR and MS[163-166]
No connection of RBP4 with obesity, IR, or components of the MS[167-171]
RBP4 levels associated with inflammatory response in obese individuals[168,172]
Circulating RBP4 levels higher in subjects with NAFLDRBP4 liver expression higher in moderate/severe NASH compared to mild forms[173]
RBP4 level a risk factors for fibrosis ≥ 2 in NASHRBP4 and HOMA-IR independently associated with steatosis in patients with chronic hepatitis C[174]
In NAFLD patients, serum RBP4 significantly lower compared with controls, did not correlate with IRRBP4 liver tissue expression enhanced in NAFLD patients and correlated with NAFLD histology[175]
Serum RBP4 levels did not correlate with BMI, HOMA-IR, fasting blood glucose, or insulin levels in patients with simple steatosis and NASHPatients with cirrhosis and fibrosis had higher RBP4 compared to controls[176,177]